[go: up one dir, main page]

WO2012087255A3 - Pharmaceutical formulations comprising imatinib - Google Patents

Pharmaceutical formulations comprising imatinib Download PDF

Info

Publication number
WO2012087255A3
WO2012087255A3 PCT/TR2011/000274 TR2011000274W WO2012087255A3 WO 2012087255 A3 WO2012087255 A3 WO 2012087255A3 TR 2011000274 W TR2011000274 W TR 2011000274W WO 2012087255 A3 WO2012087255 A3 WO 2012087255A3
Authority
WO
WIPO (PCT)
Prior art keywords
imatinib
pharmaceutical formulations
excipient
weight
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2011/000274
Other languages
French (fr)
Other versions
WO2012087255A2 (en
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2012087255A2 publication Critical patent/WO2012087255A2/en
Publication of WO2012087255A3 publication Critical patent/WO2012087255A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to imatinib formulations comprising a pharmaceutically acceptable disintegrant in the range of 0.1% to 5% by weight and at least one other excipient.
PCT/TR2011/000274 2010-12-20 2011-12-19 Pharmaceutical formulations Ceased WO2012087255A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/10618A TR201010618A2 (en) 2010-12-20 2010-12-20 An oral dosage form comprising imatinib and the manufacture of an oral dosage form
TR2010/10618 2010-12-20

Publications (2)

Publication Number Publication Date
WO2012087255A2 WO2012087255A2 (en) 2012-06-28
WO2012087255A3 true WO2012087255A3 (en) 2012-08-16

Family

ID=45529174

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/TR2011/000274 Ceased WO2012087255A2 (en) 2010-12-20 2011-12-19 Pharmaceutical formulations
PCT/TR2011/000275 Ceased WO2012087256A2 (en) 2010-12-20 2011-12-19 Pharmaceutical capsule formulations
PCT/TR2011/000276 Ceased WO2012087257A2 (en) 2010-12-20 2011-12-19 Oral dosage form comprising imatinib and production of said oral dosage form

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/TR2011/000275 Ceased WO2012087256A2 (en) 2010-12-20 2011-12-19 Pharmaceutical capsule formulations
PCT/TR2011/000276 Ceased WO2012087257A2 (en) 2010-12-20 2011-12-19 Oral dosage form comprising imatinib and production of said oral dosage form

Country Status (2)

Country Link
TR (1) TR201010618A2 (en)
WO (3) WO2012087255A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL394169A1 (en) * 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością The pharmaceutical composition of imatinib mesylate for filling unit dosage forms and the method for its preparation
KR20140065862A (en) * 2012-11-22 2014-05-30 에스케이케미칼주식회사 Effervescent quick-dissoving imatinib preparation
GB201304699D0 (en) * 2013-03-15 2013-05-01 Remedica Ltd Pharmaceutical compositions
ES2683361T3 (en) * 2013-05-14 2018-09-26 Hetero Research Foundation Imatinib compositions
WO2015004556A1 (en) * 2013-07-09 2015-01-15 Shilpa Medicare Limited Oral pharmaceutical compositions comprising imatinib mesylate
TWI608849B (en) * 2014-06-16 2017-12-21 國邑藥品科技股份有限公司 High drug load pharmaceutical compositions with controllable release rate and production methods thereof
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules
WO2019229648A1 (en) * 2018-05-28 2019-12-05 Shivalik Rasayan Limited Oral compositions of imatinib mesylate
WO2022260667A1 (en) * 2021-06-10 2022-12-15 Hikma Pharmaceuticals Usa Inc. Oral dosage forms of ibrutinib

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275372A1 (en) * 2005-06-03 2006-12-07 Elan Pharma International Limited Nanoparticulate imatinib mesylate formulations
US20070036850A1 (en) * 2005-08-15 2007-02-15 Siegfried Generics International Ag Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound
US20090087489A1 (en) * 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions
US20090221519A1 (en) * 1999-12-27 2009-09-03 Novartis Ag Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (en) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (en) * 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
GB2398565A (en) 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
US20060223817A1 (en) 2006-05-15 2006-10-05 Chemagis Ltd. Crystalline imatinib base and production process therefor
US20090324718A1 (en) * 2006-09-01 2009-12-31 Ilan Zalit Imatinib compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221519A1 (en) * 1999-12-27 2009-09-03 Novartis Ag Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound
US20060275372A1 (en) * 2005-06-03 2006-12-07 Elan Pharma International Limited Nanoparticulate imatinib mesylate formulations
US20070036850A1 (en) * 2005-08-15 2007-02-15 Siegfried Generics International Ag Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound
US20090087489A1 (en) * 2007-09-25 2009-04-02 Bella Gerber Imatinib compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Stable Tablet Formulation containing more than 80% of Imatinib mesylate", IP.COM JOURNAL, IP.COM INC., WEST HENRIETTA, NY, US, 19 February 2008 (2008-02-19), XP013123894, ISSN: 1533-0001 *

Also Published As

Publication number Publication date
WO2012087257A3 (en) 2012-09-27
WO2012087256A3 (en) 2012-09-27
WO2012087255A2 (en) 2012-06-28
WO2012087256A2 (en) 2012-06-28
WO2012087257A2 (en) 2012-06-28
TR201010618A2 (en) 2012-07-23

Similar Documents

Publication Publication Date Title
WO2012087255A3 (en) Pharmaceutical formulations comprising imatinib
WO2012021715A3 (en) Stable formulations of linaclotide
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
IL209054A0 (en) Solid pharmaceutical formulations comprising bibw 2992
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
WO2010146179A3 (en) Solid pharmaceutical composition comprising rivaroxaban
WO2012051559A3 (en) Compositions and methods of treating pulmonary hypertension
WO2011110939A3 (en) Pharmaceutical compositions of substituted benzhydrylpiperazines
NI201100227A (en) SOLID PHARMACEUTICAL FIXED DOSE COMPOSITIONS INCLUDING IRBESARTAN AND AMLODIPINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
WO2013106068A3 (en) Therapeutic compositions of specified herbal formulations and uses thereof
WO2012101653A3 (en) Modified release pharmaceutical compositions memantine
EP2241310A3 (en) Modified release formulations of emoxypine
WO2013057741A3 (en) Pharmaceutical compositions of ursodeoxycholic acid
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2010049449A3 (en) Novel salts of sunitinib
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
WO2011064558A3 (en) Pharmaceutical composition
JO3587B1 (en) Oral dosage forms of bendamustine
EP2196463A4 (en) Preparation of 5,6-dimethylxanthone-4-acetic acid, the derivatives prepared and pharmaceutical formulations thereof
WO2010079433A3 (en) Pharmaceutical composition comprising melogliptin
WO2010149794A3 (en) Novel pharmaceutical composition comprising poly (allylamin-co-n,n'-diallyl- 1,3-diamino-2-hydroxypropane)
GB2495651B (en) A novel herbal formulation advocated for the prevention and management of coronary heart disease
WO2011156045A3 (en) Tablet formulation of ezatiostat

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11811588

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11811588

Country of ref document: EP

Kind code of ref document: A2